标签归档：tyroserleutide

Tyroserleutide TFA(Synonyms: 酪丝亮肽三氟乙酸盐)

发表于由

Tyroserleutide TFA;(Synonyms: 酪丝亮肽三氟乙酸盐)

Tyroserleutide TFA 可从猪脾脏的降解产物中分离得到，是一种小分子三肽，在体内外均可抑制肿瘤生长。

Tyroserleutide TFAamp;;(Synonyms: 酪丝亮肽三氟乙酸盐)

Tyroserleutide TFA Chemical Structure

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Tyroserleutide TFA 的其他形式现货产品:

Tyroserleutide hydrochloride

生物活性

Tyroserleutide TFA, isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].

IC50 Target

Antitumor tripeptide[1][2]
体外研究
(In Vitro)

Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1].
Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2].
Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2].
Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1]
Dosage: 10, 20, 40, and 80 μg/kg
Administration: Injection (i.p.) one time every day until mice were dead.
Result: Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively.

Clinical Trial

分子量

495.45

Formula

C20H28F3N3O8
中文名称

酪丝亮肽三氟乙酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.

    [2]. Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.

Tyroserleutide hydrochloride(Synonyms: 酪丝亮肽盐酸盐)

发表于由

Tyroserleutide hydrochloride;(Synonyms: 酪丝亮肽盐酸盐) 纯度: 99.47%

Tyroserleutide hydrochloride 可从猪脾脏的降解产物中分离得到，是一种小分子三肽，在体内外均可抑制肿瘤生长。

Tyroserleutide hydrochlorideamp;;(Synonyms: 酪丝亮肽盐酸盐)

Tyroserleutide hydrochloride Chemical Structure

CAS No. : 852982-42-4

规格 价格 是否有货 数量
1 mg ￥1100 In-stock
5 mg ￥2300 In-stock
10 mg ￥4000 In-stock
25 mg ￥7500 In-stock
50 mg ￥11500 In-stock
100 mg ￥19500 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Tyroserleutide hydrochloride 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Tyroserleutide hydrochloride, isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].

IC50 Target

Antitumor tripeptide[1][2]
体外研究
(In Vitro)

Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1].
Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2].
Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2].
Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1]
Dosage: 10, 20, 40, and 80 μg/kg
Administration: Injection (i.p.) one time every day until mice were dead.
Result: Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively.

Clinical Trial

分子量

417.88

Formula

C18H28ClN3O6
CAS 号

852982-42-4
中文名称

酪丝亮肽盐酸盐
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Protect from light, stored under nitrogen

Powder -80deg;C 2 years
-20deg;C 1 year

*In solvent : -80deg;C, 6 months; -20deg;C, 1 month (protect from light, stored under nitrogen)
溶解性数据
In Vitro:;

DMSO : 250 mg/mL (598.26 mM; Need ultrasonic)

H2O : 2 mg/mL (4.79 mM; ultrasonic and warming and heat to 60°C)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3930 mL 11.9652 mL 23.9303 mL
5 mM 0.4786 mL 2.3930 mL 4.7861 mL
10 mM 0.2393 mL 1.1965 mL 2.3930 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.98 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.98 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.

    [2]. Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.

Tyroserleutide(Synonyms: 酪丝亮肽)

发表于由

Tyroserleutide;(Synonyms: 酪丝亮肽)

Tyroserleutide (YSL)，可从猪脾脏的降解产物中分离得到，是一种小分子三肽，在体内外均可抑制肿瘤生长。

Tyroserleutideamp;;(Synonyms: 酪丝亮肽)

Tyroserleutide Chemical Structure

CAS No. : 138168-48-6

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Tyroserleutide 的其他形式现货产品:

Tyroserleutide hydrochloride

生物活性

Tyroserleutide (YSL), isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].

IC50 Target

Antitumor tripeptide[1][2]
体外研究
(In Vitro)

Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1].
Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2].
Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2].
Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1]
Dosage: 10, 20, 40, and 80 μg/kg
Administration: Injection (i.p.) one time every day until mice were dead.
Result: Survival times are 25.53±14.14, 25.82±14.29, 30.47±17.89, 35.06±20.90 days for 10, 20, 40, and 80 μg/kg, respectively.

Clinical Trial

分子量

381.42

Formula

C18H27N3O6
CAS 号

138168-48-6
中文名称

酪丝亮肽
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent Solubility
In Vitro:;

H2O

Peptide Solubility and Storage Guidelines:

1.;;Calculate the length of the peptide.

2.;;Calculate the overall charge of the entire peptide according to the following table:

; Contents Assign value
Acidic amino acid Asp (D), Glu (E), and the C-terminal -COOH. -1
Basic amino acid Arg (R), Lys (K), His (H), and the N-terminal -NH2 +1
Neutral amino acid Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) 0

3.;;Recommended solution:

Overall charge of peptide Details
Negative (lt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, add NH4OH (lt;50 μL).
3.;;If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide.
Positive (gt;0) 1.;;Try to dissolve the peptide in water first.
2.;;If water fails, try dissolving the peptide in a 10%-30% acetic acid solution.
3.;;If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO.
Zero (=0) 1.;;Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first.
2.;;For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration.
参考文献

  • [1]. Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95.

    [2]. Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.